Treating FSGS: From Steroids to Dual Endothelin Angiotensin Receptor Antagonists and What Comes Next
Kirk Campbell, MD
Jai Radhakrishnan, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
CKD-aP or Something Else? Decoding the Diagnosis
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Leonie Kraft, MD
CKD-aP: Beyond the Surface
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Potassium Binders: Safety Comes First!
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Patrick Rossignol, MD, PhD
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
The Critical Interplay: CKD, HF, and HyperkaleAmia
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.